Media release ZURICH, SWITZERLAND - 18 FEBRUARY 2013 Nobel Biocare Board of Directors nominates candidates for election as members of the Board at the Annual General Meeting 2013 Nobel Biocare announced today that Oskar K. Ronner has withdrawn his shareholder proposal and informed the Board that he and his two proposed candidates will not run for election to the Board of Directors of the Company. The Board acknowledges this decision although it would have welcomed Mr. Ronner joining the Board. All current members of the Board of Directors will stand for re-election at the Annual General Meeting on 28 March 2013. As already announced on 18 January 2013, Franz Maier will be proposed as a new member of the Board. The invitation to the Annual General Meeting and the complete agenda will be published in late February. After the General Meeting, the Board of Directors will constitute itself and will elect Dr. Rolf Watter as Chairman of the Board of Directors. It will also decide on the committees and their composition. For further information, please contact: Süha Demokan VP Investor and Corporate Relations Tel.: +41 43 211 42 30, +41 79 430 81 46 firstname.lastname@example.org Disclaimer This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements. Nobel Biocare (NOBN, SIX Swiss Exchange) is a world leader in innovative restorative and esthetic dental solutions. As a complete solutions provider, Nobel Biocare offers the most comprehensive range of solutions from tooth to root, for single tooth to fully edentulous indications. The solutions portfolio covers dental implants (including the key brands NobelActive®, Brånemark System® and NobelReplace®, individualized prosthetics and equipment (NobelProcera® guided surgery solutions and biomaterials). Nobel Biocare has approximately 2'500 employees and recorded revenue of EUR 569.2 million in 2011. The company is headquartered in Zurich, Switzerland. Production takes place at seven sites located in Canada, Israel, Japan, Sweden, and the US. Nobel Biocare has 34 direct sales organizations. Media release (PDF) Provider Channel Contact Tensid Ltd., Switzerland newsbox.ch Provider/Channel related enquiries www.tensid.ch www.newsbox.ch email@example.com +41 41 763 00 50
Nobel Biocare Board of Directors nominates candidates for electi
Press spacebar to pause and continue. Press esc to stop.